Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma

Table 1 SLC22A18 methylation status and clinicopathological findings in 30 patients with glioma

Patient no.	Age (yr)	Sex	Tumor size(cm)	Recurrence within six months	Pathological grade	Methylation status	*SLC22A18* protein expression rate (%)
							Glioma	Adjacent brain tissue
1	53	M	3.5 × 4 × 3	+	IV	+	4	33
3	42	M	3 × 4.5 × 5	+	III	+	25	58
8	38	F	3.5 × 3 × 3	+	III	+	35	62
9	49	M	3 × 4 × 3	+	IV	+	3	42
10	58	M	5.5 × 4 × 4	-	II	+	39	67
15	69	M	3.5 × 4 × 3	+	IV	+	8	38
17	32	M	5 × 6 × 4	-	II	+	37	65
19	45	F	4 × 5 × 6	-	II	+	34	59
20	51	M	4.5 × 5 × 6	+	IV	+	0	25
21	43	M	3.5 × 4 × 5	+	IV	+	9	35
24	48	M	3.5 × 4 × 4	-	II	+	32	61
25	55	F	3.5 × 4 × 5	-	II	+	30	59
27	62	F	4 × 4 × 3	+	IV	+	0	30
29	34	M	5 × 4 × 3	-	II	+	37	65
30	39	M	3.5 × 2 × 3	+	IV	+	6	38
2	71	M	2 × 3 × 4	-	I	-	45	68
4	33	M	3 × 4 × 5	-	II	-	32	61
5	43	M	3 × 4 × 6	-	I	-	46	62
6	46	F	3.5 × 4 × 4	+	III	-	25	57
7	48	M	4.5 × 4 × 5	-	II	-	37	68
11	47	F	5.5 × 5 × 6	+	IV	-	12	54
12	57	M	5 × 6 × 5	-	II	-	32	70
13	56	M	3.5 × 5 × 6	-	I	-	52	75
14	46	M	3.5 × 5 × 4	-	I	-	45	72
16	57	M	3 × 3 × 4	+	IV	-	14	62
18	53	M	3 × 4 × 5	-	I	-	52	78
22	54	F	5.5 × 6 × 5	-	I	-	48	73
23	65	M	3 × 4 × 3	+	III	-	34	65
26	46	F	3.5 × 5 × 4	-	I	-	52	82
28	62	M	3 × 4.5 × 5	+	III	-	29	62

ISSN: 1479-5876